News

Californian company RapidAI announces launch of new clinical decision support platform

RapidAI, a Californian AI and tech company, has announced milestones in advancing deep clinical AI, including the launch of a new AI healthcare platform and an AI solution to help identify suspected stroke cases at CT.

The company is celebrating the launch of its new AI-based healthcare platform, Rapid Edge Cloud, which offers clinical decision support, third party integration of additional AI systems, and the functionality for on-premises AI services “to continue in the event a hospital needs to cut off cloud connectivity” to prevent disruption to care.

RapidAI has also highlighted the benefits of its new offering of non-contrast CT solutions for stroke, which utilises AI to help identify suspected stroke cases at the first CT scan, potentially reducing the time taken for patients to receive treatment and improving outcomes.

In Japan, RapidAI’s advanced stroke imaging platform for support of mechanical thrombectomy determination, has achieved Class III Shonin clearance, meaning that it can now be accessed by Japanese clinicians for their advanced imaging needs.

Karim Karti, CEO of RapidAI, said: “While celebrating a year of significant achievements, we have also been working tirelessly behind the scenes to prepare for the next phase of innovation and expansion into new disease states. Our breakthrough AI, cutting-edge approach and Edge Cloud technology platform will take clinical decision support deeper than ever before and play a crucial role in transforming the landscape of care across diseases.” 

Also from the US, health tech company Oracle has announced that it will be harnessing generative AI technology to help clinicians reduce administrative pressures, as well as making it easier for patients to schedule appointments and check clinical information using simple voice commands.

Elsewhere, medical device company EndoQuest Robotics from Houston, Texas, has announced the successful closure of a $42 million C-1 preferred financing round, with the strategic funding set to help advance its flexible endoluminal robot which is designed to support minimally invasive procedures.